Portal de Periódicos da CAPES

Artigo Acesso aberto Produção Nacional Revisado por pares

BIBTEX RIS

Double-blind, Randomized, Placebo-controlled Trial With N-acetylcysteine for Treatment of Severe Acute Respiratory Syndrome Caused by Coronavirus Disease 2019 (COVID-19)

2020; Oxford University Press; Volume: 72; Issue: 11 Linguagem: Inglês

10.1093/cid/ciaa1443

1537-6591

Júlio César Garcia de Alencar, Claudia de Lucena Moreira, Alicia Dudy Müller, Cleuber Esteves Chaves, Marina Akemi Fukuhara, Elizabeth Aparecida da Silva, Maria de Fátima Silva Miyamoto, Vanusa Barbosa Pinto, Cauê Gasparotto Bueno, Felippe Lazar Neto, Luz Marina Gómez Gómez, Maria Clara Saad Menezes, Júlio Flávio Meirelles Marchini, Lucas Oliveira Marino, Rodrigo Antônio Brandão Neto, Heraldo Possolo de Souza, Fernando Salvetti Valente, Hassan Rahhal, Juliana Batista Rodrigues Pereira, Eduardo Messias Hirano Padrão, Annelise Passos Bispos Wanderley, Bruno Marques, Luz Marina Gómez Gómez, Edwin Albert D’Souza, Arthur Petrillo Bellintani, Rodrigo Cezar Miléo, Rodrigo Werner Toccoli, Fernanda Máximo Fonseca e Silva, João Martelleto Baptista, Marcelo de Oliveira Silva, Giovanna Babikian Costa, Rafael Berenguer Luna, Henrique Tibucheski dos Santos, Mariana Mendes Gonçalves Cimatti De Calasans, Marcelo Petrof Sanches, Diego Juniti Takamune, Luiza Boscolo, Pedro Antonio Araújo Simões, Manuela Cristina Adsuara Pandolfi, Beatriz Larios Fantinatti, Gabriel Travessini, Matheus Finardi Lima de Faria, Lígia Trombetta Lima, Bianca Ruiz Nicolao, Gabriel de Paula Maroni Escudeiro, João Pedro Afonso Nascimento, Bruna Tolentino Caldeira, Laura de Góes Campos, Vitor Macedo Brito Medeiros, Tales Cabral Monsalvarga, Isabela Harumi Omori, Diogo Visconti Guidotte, Alexandre L. Bortolotto, Rodrigo de Abreu, Nilo Arthur Bezerra Martins, Carlos Eduardo Umehara Juck, Lucas de Oliveira Utiyama, Felipe Mouzo Bortoleto, Renan Dourado Tinel, Gabriel Martinez Andreola, Natalia Paula Cardoso, Osvaldo Santistevan Claure, João Vítor Ziroldo Lopes, Sabrina Corrêa da Costa Ribeiro,

SARS-CoV-2 and COVID-19 Research

A local increase in angiotensin 2 after inactivation of angiotensin-converting enzyme 2 by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may induce a redox imbalance in alveolar epithelium cells, causing apoptosis, increased inflammation and, consequently, impaired gas exchange. We hypothesized that N-acetylcysteine (NAC) administration could restore this redox homeostasis and suppress unfavorable evolution in patients with coronavirus disease 2019 (COVID-19).This was a double-blind, randomized, placebo-controlled, single-center trial conducted at the Emergency Department of Hospital das Clínicas, São Paulo, Brazil, to determine whether NAC in high doses can avoid respiratory failure in patients with COVID-19. We enrolled 135 patients with severe COVID-19 (confirmed or suspected), with an oxyhemoglobin saturation 24 breaths/minute. Patients were randomized to receive NAC 21 g (~300 mg/kg) for 20 hours or dextrose 5%. The primary endpoint was the need for mechanical ventilation. Secondary endpoints were time of mechanical ventilation, admission to the intensive care unit (ICU), time in ICU, and mortality.Baseline characteristics were similar between the 2 groups, with no significant differences in age, sex, comorbidities, medicines taken, and disease severity. Also, groups were similar in laboratory tests and chest computed tomography scan findings. Sixteen patients (23.9%) in the placebo group received endotracheal intubation and mechanical ventilation, compared with 14 patients (20.6%) in the NAC group (P = .675). No difference was observed in secondary endpoints.Administration of NAC in high doses did not affect the evolution of severe COVID-19.Brazilian Registry of Clinical Trials (REBEC): U1111-1250-356 (http://www.ensaiosclinicos.gov.br/rg/RBR-8969zg/).